微泡相关组织因子与特鲁索综合征
Microvesicle-associated tissue factor and Trousseau's syndrome.
作者信息
Del Conde I, Bharwani L D, Dietzen D J, Pendurthi U, Thiagarajan P, López J A
机构信息
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
出版信息
J Thromb Haemost. 2007 Jan;5(1):70-4. doi: 10.1111/j.1538-7836.2006.02301.x.
Abstract
BACKGROUND
Trousseau's syndrome is a prothrombotic state associated with malignancy that is poorly understood pathophysiologically.
METHODS AND RESULTS
Here we report studies on the blood of a 55-year-old man with giant-cell lung carcinoma who developed a severe form of Trousseau's syndrome. His clinical course was dominated by an extremely hypercoagulable state. Despite receiving potent antithrombotic therapy, he suffered eleven major arterial and venous thrombotic events over a 5 month period. We examined the patient's blood for tissue factor (TF), the major initiator of coagulation, and found its concentration in his plasma to be forty-one-fold higher than the mean concentration derived from testing of 16 normal individuals.
CONCLUSION
Almost all of the TF in the patient's plasma was associated with cell-derived microvesicles, likely shed by the cancer cells.
摘要
背景
特鲁索综合征是一种与恶性肿瘤相关的血栓前状态，其病理生理学机制尚不清楚。
方法与结果
在此我们报告对一名55岁巨细胞肺癌男性患者血液的研究，该患者发生了严重形式的特鲁索综合征。他的临床病程以极度高凝状态为主。尽管接受了强效抗血栓治疗，但在5个月内他仍发生了11次主要的动脉和静脉血栓事件。我们检测了患者血液中的组织因子（TF），它是凝血的主要启动因子，发现其血浆浓度比16名正常个体检测所得的平均浓度高41倍。
结论
患者血浆中几乎所有的TF都与细胞衍生的微泡相关，这些微泡可能是由癌细胞脱落产生的。
相似文献
1
Microvesicle-associated tissue factor and Trousseau's syndrome.微泡相关组织因子与特鲁索综合征
J Thromb Haemost. 2007 Jan;5(1):70-4. doi: 10.1111/j.1538-7836.2006.02301.x.
2
Pathophysiology of Trousseau's syndrome.特鲁索综合征的病理生理学
Hamostaseologie. 2015;35(1):52-9. doi: 10.5482/HAMO-14-08-0037. Epub 2014 Nov 18.
3
Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma.与肺腺癌产生的组织因子相关的特鲁索综合征。
Thorax. 2006 Nov;61(11):1009-10. doi: 10.1136/thx.2004.031492.
4
Internal jugular venous thrombosis due to Trousseau's syndrome as the presenting feature of metastatic prostate carcinoma: a case report.以特鲁索综合征所致颈内静脉血栓形成作为转移性前列腺癌的首发表现：一例病例报告。
J Med Case Rep. 2016 Apr 21;10(1):104. doi: 10.1186/s13256-016-0884-9.
5
Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis.组织因子：止血的必要介质和血栓形成的触发因子。
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):709-725. doi: 10.1161/ATVBAHA.117.309846. Epub 2018 Feb 8.
6
Tissue Factor Prothrombotic Activity Is Regulated by Integrin-arf6 Trafficking.组织因子促血栓形成活性受整合素-arf6转运调控。
Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1323-1331. doi: 10.1161/ATVBAHA.117.309315. Epub 2017 May 11.
7
Trousseau's syndrome associated with rapidly emerging pancreatic adenocarcinoma soon after esophagectomy: A case report.食管癌切除术后不久出现的与快速进展的胰腺腺癌相关的特鲁索综合征：一例报告。
Int J Surg Case Rep. 2020;77:605-609. doi: 10.1016/j.ijscr.2020.11.113. Epub 2020 Nov 22.
8
Tissue factor as a tumor procoagulant.组织因子作为一种肿瘤促凝剂。
Cancer Metastasis Rev. 1992 Nov;11(3-4):249-66. doi: 10.1007/BF01307181.
9
Trousseau's syndrome and acute arterial thrombosis.特鲁索综合征与急性动脉血栓形成。
Cardiovasc Surg. 2000 Apr;8(3):214-8. doi: 10.1016/s0967-2109(00)00004-1.
10
Trousseau's syndrome in a non-small cell lung cancer patient aggravated by pembrolizumab.一名非小细胞肺癌患者的特鲁索综合征因帕博利珠单抗而加重。
J Oncol Pharm Pract. 2023 Jan;29(1):233-238. doi: 10.1177/10781552221102311. Epub 2022 May 20.
引用本文的文献
1
Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer.血小板在肺癌中的促肿瘤生成和促血栓形成作用。
Int J Mol Sci. 2023 Jul 25;24(15):11927. doi: 10.3390/ijms241511927.
2
Evaluation of four commercial ELISAs to measure tissue factor in human plasma.评估四种用于检测人血浆中组织因子的商业酶联免疫吸附测定法。
Res Pract Thromb Haemost. 2023 Mar 28;7(3):100133. doi: 10.1016/j.rpth.2023.100133. eCollection 2023 Mar.
3
The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans.癌症中的组织因子途径：硫酸乙酰肝素蛋白聚糖的概述及作用
Cancers (Basel). 2023 Feb 28;15(5):1524. doi: 10.3390/cancers15051524.
4
Contrasts in Glioblastoma-Venous Thromboembolism versus Bleeding Risk.胶质母细胞瘤-静脉血栓栓塞与出血风险的对比。
Cells. 2021 Jun 7;10(6):1414. doi: 10.3390/cells10061414.
5
Importance of Standard Treatment in Prognosis of Patients with Ovarian Cancer and Associated Cerebral Infarction.卵巢癌合并脑梗死患者预后的标准治疗的重要性。
Clin Interv Aging. 2020 Feb 5;15:151-157. doi: 10.2147/CIA.S229236. eCollection 2020.
6
Biology and Role of Extracellular Vesicles (EVs) in the Pathogenesis of Thrombosis.细胞外囊泡（EVs）在血栓形成发病机制中的生物学作用和角色。
Int J Mol Sci. 2019 Jun 11;20(11):2840. doi: 10.3390/ijms20112840.
7
Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models.预测癌症患者的静脉血栓栓塞：候选生物标志物和风险评估模型。
Cancers (Basel). 2019 Jan 15;11(1):95. doi: 10.3390/cancers11010095.
8
Clinical Features of Cancer Associated Ischemic Stroke.癌症相关性缺血性卒中的临床特征
Noro Psikiyatr Ars. 2018 May 4;55(2):113-117. doi: 10.29399/npa.22999. eCollection 2018.
9
Microparticles as Biomarkers of Blood Coagulation in Cancer.微粒作为癌症中血液凝固的生物标志物
Biomark Cancer. 2015 Oct 1;7:51-6. doi: 10.4137/BIC.S30347. eCollection 2015.
10
Trousseau's Syndrome, a Previously Unrecognized Condition in Acute Ischemic Stroke Associated With Myocardial Injury.特鲁索综合征，一种急性缺血性卒中中与心肌损伤相关的先前未被认识的病症。
J Investig Med High Impact Case Rep. 2014 Jun 24;2(2):2324709614539283. doi: 10.1177/2324709614539283. eCollection 2014 Apr-Jun.
本文引用的文献
1
Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.携带组织因子的微泡源自脂筏，并与活化血小板融合以启动凝血。
Blood. 2005 Sep 1;106(5):1604-11. doi: 10.1182/blood-2004-03-1095. Epub 2005 Mar 1.
2
Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial.
Eur Heart J. 2005 Apr;26(7):682-8. doi: 10.1093/eurheartj/ehi094. Epub 2005 Jan 31.
3
Carcinoma of the body of the pancreas with fibrin thrombosis and fibrinogenopenia.伴有纤维蛋白血栓形成和纤维蛋白原减少的胰体癌
Cancer. 1953 Sep;6(5):862-9. doi: 10.1002/1097-0142(195309)6:5<862::aid-cncr2820060503>3.0.co;2-2.
4
Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.选择素-黏蛋白相互作用可能是特鲁索综合征与黏液腺癌关联的分子学解释。
J Clin Invest. 2003 Sep;112(6):853-62. doi: 10.1172/JCI18882.
5
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.替法可吉（重组组织因子途径抑制剂）治疗严重脓毒症的疗效和安全性：一项随机对照试验。
JAMA. 2003 Jul 9;290(2):238-47. doi: 10.1001/jama.290.2.238.
6
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.组织因子在体内发展中的血栓内的积累取决于微粒P-选择素糖蛋白配体1和血小板P-选择素。
J Exp Med. 2003 Jun 2;197(11):1585-98. doi: 10.1084/jem.20021868.
7
Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.可变剪接的人组织因子：一种循环的、可溶性的、促血栓形成蛋白。
Nat Med. 2003 Apr;9(4):458-62. doi: 10.1038/nm841. Epub 2003 Mar 24.
8
9
Localization of tissue factor in actin-filament-rich membrane areas of epithelial cells.组织因子在上皮细胞富含肌动蛋白丝的膜区域中的定位。
Exp Cell Res. 1999 Apr 10;248(1):136-47. doi: 10.1006/excr.1999.4395.
10
Zotero 插件